Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system

Rahimi, Hossein; Salehiabar, Marziyeh; Charmi, Jalil; Barsbay, Murat; Ghaffarlou, Mohammadreza; Razlighi, Mahdi Roohi; Davaran, Soodabeh; Khalilov, Rovshan; Sugiyama, Minetaka; Nosrati, Hamed; Kaboli, Saeed; Danafar, Hossein; Webster, Thomas J.

doi:10.1016/j.nantod.2020.100895

Cited by 57 publications

(33 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple techniques have been developed for CRISPR delivery such as physical, viral, and non-viral delivery systems ( 99 ). Physical methods include microinjection, transfection, and electroporation that are most suitable for research purposes in cell culture.…”

Section: Crispr Delivery Approaches and Challengesmentioning

confidence: 99%

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Yang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Cancer is one of the most leading causes of mortalities worldwide. It is caused by the accumulation of genetic and epigenetic alterations in 2 types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. In recent years, development of the clustered regularly interspaced short palindromic repeats (CRISPR) technology has revolutionized genome engineering for different cancer research ranging for research ranging from fundamental science to translational medicine and precise cancer treatment. The CRISPR/CRISPR associated proteins (CRISPR/Cas) are prokaryote-derived genome editing systems that have enabled researchers to detect, image, manipulate and annotate specific DNA and RNA sequences in various types of living cells. The CRISPR/Cas systems have significant contributions to discovery of proto-oncogenes and TSGs, tumor cell epigenome normalization, targeted delivery, identification of drug resistance mechanisms, development of high-throughput genetic screening, tumor models establishment, and cancer immunotherapy and gene therapy in clinics. Robust technical improvements in CRISPR/Cas systems have shown a considerable degree of efficacy, specificity, and flexibility to target the specific locus in the genome for the desired applications. Recent developments in CRISPRs technology offers a significant hope of medical cure against cancer and other deadly diseases. Despite significant improvements in this field, several technical challenges need to be addressed, such as off-target activity, insufficient indel or low homology-directed repair (HDR) efficiency, in vivo delivery of the Cas system components, and immune responses. This study aims to overview the recent technological advancements, preclinical and perspectives on clinical applications of CRISPR along with their advantages and limitations. Moreover, the potential applications of CRISPR/Cas in precise cancer tumor research, genetic, and other precise cancer treatments discussed.

show abstract

Section: Crispr Delivery Approaches and Challengesmentioning

confidence: 99%

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Yang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Generally, there are three different approaches for CRISPR/Cas 9 delivery [318]. The ultimate goal is to transfer the whole system into the cells.…”

Section: Future Perspectivesmentioning

confidence: 99%

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Mohammadinejad

Dehshahri

Madamsetty

et al. 2020

Journal of Controlled Release

191

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

“…Another vehicle is using nanoparticles to directly deliver the Cas effectors and crRNA molecules into the target bacterial cells ( Figure 2B ). With the rapid development of nanotechnology, multiple nanoparticles, such as the cationic polymer-based nanoparticles and inorganic nanoparticles, have been readily accessible to transfer the necessary components of CRISPR-Cas systems ( Lee et al, 2017 ; Rahimi et al, 2020 ). It was shown that a cationic polymer-based nanosized CRISPR complex which carries the Cas9 protein and crRNA can be successfully introduced into MRSA in vitro and is functional to execute bacterial killing by targeting the methicillin-resistant gene ( Kang et al, 2017 ).…”

Section: Challenges In the Delivery Of Crispr-cas Antimicrobialsmentioning

confidence: 99%

Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance

et al. 2021

View full text Add to dashboard Cite

The emergence of antimicrobial-resistant (AMR) bacteria has become one of the most serious threats to global health, necessitating the development of novel antimicrobial strategies. CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) system, known as a bacterial adaptive immune system, can be repurposed to selectively target and destruct bacterial genomes other than invasive genetic elements. Thus, the CRISPR-Cas system offers an attractive option for the development of the next-generation antimicrobials to combat infectious diseases especially those caused by AMR pathogens. However, the application of CRISPR-Cas antimicrobials remains at a very preliminary stage and numerous obstacles await to be solved. In this mini-review, we summarize the development of using type I, type II, and type VI CRISPR-Cas antimicrobials to eradicate AMR pathogens and plasmids in the past a few years. We also discuss the most common challenges in applying CRISPR-Cas antimicrobials and potential solutions to overcome them.

show abstract

Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system

Cited by 57 publications

References 188 publications

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance

Contact Info

Product

Resources

About